Eylea biosimilar by Samsung Bioepis, now FDA-approved, will stay on hold
The US Court of Appeals for the Federal Circuit today refused to undo a preliminary injunction barring South Korea-based Samsung Bioepis, or SB, from launching in the US a biosimilar to...To view the full article, register now.
Already a subscriber? Click here to view full article